About
About Apeloa Pharmaceutical Co.,Ltd
Apeloa Pharmaceutical Co.,Ltd provides raw materials various pharmaceutical factories in the People's Republic of China and internationally. The company operates through API, CDMO, and Pharmaceutical segments. It offers API intermediates business, which includes cephalosporin, penicillin, psychotropic, cardiovascular and cerebrovascular, and veterinary API intermediates series; innovative drug R&D and production services CDMO include R&D services, commercial human drug projects, commercial veterinary drug projects and other commercial projects; pharmaceutical business includes anti-infective, cardiovascular, psychotropic, hepatobiliary and anti-tumor categories. The company also provides technology platforms, such as flow chemistry, synthetic biology and biocatalysis, crystallization and particle engineering, peptide, high potency compound, conjugate library service, oligonucleotide synthesis, and preparation and purification; and controlled-release formulation development, taste masking technology, and particle flow simulation. In addition, it exports its products under the Tianliwei, Baishixin, Li'an, Jutai, and other brands. Apeloa Pharmaceutical Co.,Ltd was founded in 1989 and is based in Dongyang, the People's Republic of China.
Visit company website
5 years, 5 months ago
Apeloa Pharmaceutical Co.,Ltd is currently in a long term uptrend where the price is trading 10.2% above its 200 day moving average.
From a valuation standpoint, the stock is 54.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.4.
Apeloa Pharmaceutical Co.,Ltd's total revenue rose by 15.2% to $2B since the same quarter in the previous year.
Its net income has increased by 53.2% to $187M since the same quarter in the previous year.
Finally, its free cash flow fell by 130.0% to $-83M since the same quarter in the previous year.
Based on the above factors, Apeloa Pharmaceutical Co.,Ltd gets an overall score of 4/5.